Memantine is a drug that has been used to treat Alzheimer’s disease since the early 1990s. It is an NMDA receptor antagonist, which means it blocks the action of the neurotransmitter glutamate at the NMDA receptor. This prevents excitotoxicity, the process by which neurons become overstimulated and die. While the exact mechanism of action of memantine is still not fully understood, recent research has shed light on how it works to protect neurons and improve cognitive function. In this article, we will explore the mechanism of action of memantine and discuss the implications of this research for the treatment of Alzheimer’s disease.
The NMDA receptor is a type of glutamate receptor found in the brain. It is involved in a variety of processes, including learning and memory. Glutamate is an excitatory neurotransmitter, meaning it stimulates neurons to fire. When glutamate binds to the NMDA receptor, it causes the neuron to become overstimulated, leading to a process called excitotoxicity. Excitotoxicity is a major contributor to the death of neurons in Alzheimer’s disease. Memantine is an NMDA receptor antagonist, meaning it blocks the action of glutamate at the NMDA receptor. By blocking glutamate from binding to the NMDA receptor, memantine prevents neurons from becoming overstimulated and dying. This is thought to be the primary mechanism of action of memantine in the treatment of Alzheimer’s disease.
In addition to preventing excitotoxicity, memantine has been found to have other neuroprotective effects. One study found that memantine was able to reduce the production of amyloid beta, a protein that is thought to contribute to the development of Alzheimer’s disease. The study found that memantine was able to reduce the production of amyloid beta by up to 50%. Memantine has also been found to reduce inflammation in the brain. Inflammation is thought to play a role in the progression of Alzheimer’s disease, and memantine has been found to reduce inflammation in the brain. This could be another mechanism by which memantine is able to protect neurons from damage and death.
In addition to its neuroprotective effects, memantine has been found to improve cognitive function in people with Alzheimer’s disease. One study found that memantine was able to improve memory, attention, and language in people with mild to moderate Alzheimer’s disease. The study found that the cognitive benefits of memantine were sustained for up to three months after treatment. Another study found that memantine was able to improve executive function in people with Alzheimer’s disease. Executive function is the ability to plan, organize, and make decisions. The study found that memantine was able to improve executive function in people with mild to moderate Alzheimer’s disease.
Memantine is a drug that has been used to treat Alzheimer’s disease since the early 1990s. Recent research has shed light on how it works to protect neurons and improve cognitive function. Memantine is an NMDA receptor antagonist, which means it blocks the action of the neurotransmitter glutamate at the NMDA receptor. This prevents excitotoxicity, the process by which neurons become overstimulated and die. In addition to preventing excitotoxicity, memantine has been found to have other neuroprotective effects, such as reducing the production of amyloid beta and reducing inflammation in the brain. It has also been found to improve cognitive function in people with Alzheimer’s disease. The research on the mechanism of action of memantine has implications for the treatment of Alzheimer’s disease and could lead to more effective treatments in the future.
1.
A single-cell analysis reveals a distinctive immunosuppressive tumor microenvironment in kidney cancer brain metastases.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
According to a study by Amrita Hospital in Kochi, cancer mortality is rising among Indian women while declining for men.
5.
A garden can save your life
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
3.
Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation